In January 2020, MyBiotech GmbH, a start-up company in the biotech industry, and MJR PharmJet GmbH, experts in pharmaceutical development joined forces and will further expand their activities in biotech and pharma.
The merger will not remain the only major change in Überherrn. From 2020, own products will be developed and manufactured on site. The focus is on green technologies, e.g. for the sustainable production of omega-3 fatty acids from algae. The manufacturing of innovative, more efficient pharmaceuticals will also be tackled: “Production in the pharmaceutical sector will take place under strict regulations according to GMP. The combination of biotechnology and pharmaceutical development is unique in this form, and will help MyBiotech to further grow and expand.", said Dr. Emre Türeli, CSO of MyBiotech.
Both companies are partners of the Instillo Group, which offers a diverse and unique location with all of its members. From the development by MyBiotech GmbH and nanoSaar Lab GmbH, through the stability test by Quasaar GmbH, up to production facilities by MyBiotech GmbH, everything is done at the same industry campus. The companies are also connected through the unique and patented technology: microjet reactor. This small reactor offers a wide range of applications in chemical, pharmaceutical and biotechnological sectors.
MyBiotech GmbH was founded in 2016 on the aforementioned industry campus in Saarland. Through the Instillo Group’s large network of contacts, MyBiotech GmbH can benefits from its worldwide reach and has collaborations in over 20 countries already.
MyBiotech GmbH
Industriestr. 1b
66802 Überherrn
Telefon: +49 6836 9691145
Telefax: +49 6836 9691199
http://www.mybiotech.de
Geschäftsführer MyBiotech GmbH
Telefon: +49 (6836) 9691-145
E-Mail: d.mueller@mybiotech.de
